BACKGROUND: Plasma monitoring of @entity1499 ( @entity1500 ) levels is a standard approach to predict @entity1500 -related @entity137 in a @entity2101 ( @entity2101 ) @entity1500 monotherapy for childhood @entity981 . However, it is uncertain whether plasma @entity1500 levels can predict @entity1500 -related @entity137 in the HDMTX plus additional chemotherapy for childhood @entity1892 ( @entity1892 ). PROCEDURES: To statistically analyze the relationship between @entity1500 pharmacokinetic parameters and @entity1500 -related @entity137 , we collected data from @entity1 with delayed @entity1500 elimination (>= 1     M at 48   hr and/or >= 0.5     M at 72   hr) in the Japanese @entity706 Study Group (JPLSG) BNHL 03 study. Blood @entity1500 levels were measured at 24, 48, and 72   hr after 3 or 5   g/m(2) @entity2101 - @entity1500 administration for 24   hr. RESULTS: Three hundred and four @entity1 received 2-4 courses of the HDMTX plus additional chemotherapy, and delayed @entity1500 elimination was observed in 165 courses of 127 @entity1 . In those, nephrotoxicity was significantly correlated with plasma @entity1500 levels for each @entity1 (P   =   0.03), and also for each course (P   =   0.009), but no other @entity137 were correlated. Another analysis according to HDMTX courses showed no significant correlation between the first high plasma @entity1500 levels and subsequent @entity1500 levels in later course. It also showed that incidence of @entity99 was most frequent in the first HDMTX course, and then sharply decreased in later courses (P   <   0.001). CONCLUSIONS: Our results suggest that plasma @entity1500 level is not a reliable predictor for adverse events except for nephrotoxicity in multiple HDMTX therapy courses in childhood @entity1892 . Pediatr @entity5    2014 Wiley Periodicals, Inc.

Statistical analysis of relation between plasma @entity1499 concentration and @entity137 in XXXX @entity1499 therapy of childhood nonHodgkin lymphoma.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukemia'] @entity706 :: ('MESH:D008223', 'Disease') :: ['Pediatric Leukemia/Lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Blood Cancer'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-NHL', 'B-cell nonHodgkin lymphoma'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['HD', 'high-dose'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate'] @entity99 :: ('MESH:D056486', 'Disease') :: ['liver and gastrointestinal toxicities']
@entity2101 :: (MESH:C538394,Disease) :: ['high-dose']
